采用美国生产肿瘤标志物（ＤＲ７０ＴＭ）试剂以免疫学酶联方法对１４种癌症３５０例患者和３３５例健康人进行对照检测，其结果表明：肺癌阳性率约为８８１％；胃癌为９２８５％；乳腺癌为６５６７％；肠癌为８３３３％；肝癌为９１８９％；卵巢癌为９３７５％；食道癌为９２８５％和宫颈癌为８７５０％等，总计癌症患者阳性率约为８２２８％，与健康对照组比较，Ｐ＜０００１，差异有高度显著性。认为ＤＲ７０ＴＭ试剂可作为辅助诊断及监测肿瘤复发的指标，为临床提供参考依据。 The US-produced tumor marker (DR70TM) reagent was used for immunohistochemical analysis of 350 cancers and 335 healthy people in 14 cancers. The results showed that the positive rate of lung cancer was approximately 88.1%; 85%; Breast cancer is 6567%; Colorectal cancer is 8333%; Liver cancer is 9189%; Ovarian cancer is 9375%; Esophageal cancer is 9285%; Cervical cancer is 8750% The total positive rate of cancer patients was approximately 8228%. Compared with the healthy control group, P<0001, the difference was highly significant. It is considered that DR-70TM reagent can be used as an auxiliary diagnostic and monitoring indicator of tumor recurrence and provide a reference for clinical practice.